Posts Archive

Dec 2, 2022

NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM

MagnetisMM-8 NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in Chinese Participants With Refractory...

Dec 1, 2022

NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) Pre-approval Single-patient Expanded Access for...

Dec 1, 2022

NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients NCT05463939: Teclistamab...

Dec 1, 2022

NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Modakafusp alfa (Formerly TAK-573)...

Dec 1, 2022

NCT05308225: Phase 1/2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma This is a two-stage...

Dec 30, 2021

IFM 2020-02 MInimal Residual Disease Adapted Strategy (MIDAS) Isa-KRd NCT04934475: Phase 3 - IFM 2020-02 -MInimal Residual Disease...